JFA
TBPH icon

JNBA Financial Advisors’s Theravance Biopharma TBPH Stock Holding History

JNBA Financial Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$12 – 729
2023
Q4 		$12 Hold
1
– – ﹤0.01% 709
2023
Q3 		$9 Buy
+1
New +$10 ﹤0.01% 748

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

JNBA Financial Advisors's TBPH Position: Q1 2024 in Review

JNBA Financial Advisors sold out of Theravance Biopharma (TBPH) in Q1 2024, closing a stake of 1 share — an estimated $12 sold.

JNBA Financial Advisors first reported a position in TBPH in Q3 2023 and held it in 2 quarters. The position peaked at $12 in Q4 2023. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2024.

  • JNBA Financial Advisors reported no remaining Theravance Biopharma position as of Q1 2024 after selling out during the quarter.
  • JNBA Financial Advisors sold 1 Theravance Biopharma share in Q1 2024, an estimated $12.
  • JNBA Financial Advisors first reported a position in Theravance Biopharma in Q3 2023 and held it in 2 quarters.
  • JNBA Financial Advisors's Theravance Biopharma position peaked at $12 in Q4 2023.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2024.

Based on JNBA Financial Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.